

Date and Time: 24 July 2014 1030 - 1630

Transfusion: Blood Transfusion

Guideline Development Group Meeting 10

Place: NCGC, 180 Great Portland Street, London, W1W 5QZ

Present: Mike Murphy (Chair) MM
Jennifer Hill (Guideline lead) JH
Smita Padhi (Senior Research Fellow) SP
Sophia Kemmis-Betty (Health Economist) SW
Sharangini Rajesh (Research Fellow) SR
Tamara Diaz (Project Manager) TD

David Blackwell (Transfusion Practitioner) DB
Graham Donald (Patient Member) GD
Karen Madgwick (Transfusion Lab Scientist) KM
Kenneth Halligan (Patient Member) KH
Mary Marsden (Transfusion Nurse) MM
Helen New (Consultant Paediatrician)
Shubha Allard (Consultant Haematologist)
Timothy Walsh (Anaesthetist/Intensivist) TW

NICE Staff:	Jennifer Wells (Guidelines Coordinator)
Observers:	Bethany King (NCGC, Document Editor/Process Assistant) Lindsay Dytham (NCGC, Document Editor/Process Assistant)
Apologies:	Dafydd Thomas (Consultant Anaesthetist) DT Robert Morris (Surgeon) RM Susan Robinson (Consultant Haematologist) SRo

Notes

1. Introductions and apologies. MM welcomed the group to the 10th meeting of this GDG. Apologies were heard from SRO, RM and DT.
2. Declarations of Interests (DOIs). The Chair asked all GDG members to declare any relevant conflicts of interest since GDG 9. There were no new declarations relevant to the day's agenda and no further action was required.
3. The draft NICE minutes of GDG 9. The Minutes of GDG 9 were agreed as a true and accurate account of the meeting, pending the following change: Item 5, should read 'Evidence review: Combination treatments (tranexamic acid and cell salvage)'
4. Revision of recommendations. The GDG discussed and edited recommendations for Oral iron, IV iron, Erythropoietin, Cell salvage, tranexamic, monitoring acute reactions, platelets and fresh frozen plasma. There were limited edits to recommendations in the two following areas due to the existing conflicts of interest of GDG members: the red blood cell transfusion recommendation was changed to clarify the population to be targeted and there were no changes to the electronic patient identification and electronic decision support recommendations.
5. Evidence review: Cryoprecipitate. The clinical evidence was presented by SR. SKB presented the costs. The GDG discussed draft recommendations.

Date, time and venue of the next meeting

1. GDG 11: 17 September 2014, 1030 – 1630 in the Boardroom, NCGC offices, 180 Great Portland Street, London, W1W 5QZ.